New Clinical Data on AVEO Oncology's Tivozanib and Ficlatuzumab to be Presented at ESMO 2012 Congress

AVEO Oncology

today announced that new clinical data on its lead product candidate tivozanib, partnered with Astellas Pharma Inc. (TSE: 4503), as well as its HGF inhibitory antibody ficlatuzumab will be presented at the European Society of Medical Oncology (ESMO) 2012 Congress in Vienna, Austria, September 28 – October 2, 2012. “At this year's ESMO, investigators will present new data on both our lead product candidate tivozanib and our HGF inhibitory antibody ficlatuzumab,” said William Slichenmyer, M.D., Sc.M., chief medical officer, AVEO Oncology. “We believe the additional TIVO-1 analyses underscore the safety profile of tivozanib in RCC while the new ficlatuzumab data demonstrate its targeted inhibition of the HGF ligand. We look forward to